Gateway Biotechnology Receives Patent for Preventing Hearing Loss

 

document-agreement-documents-sign-48148

Based in Missouri, Thomas Brutnell guides Viridis Genomics Consulting and works with business and academic clients in the plant biotechnology sphere. As Gateway Biotechnology, Inc.’s vice president, Thomas Brutnell is spearheading next-generation research and development for preventing noise-induced hearing loss (NIHL) and tinnitus through innovative drug solutions. This approach uses repurposed medications with extensive safety records behind them to quickly move effective treatments to the market.

In October 2019, Gateway Biotechnology announced that it had received US patent number 10,434,097 for the development of tetrandrine (TET), a compound isolated from a plant used in traditional Chinese medicine. The patent draws on NIH-funded research that has demonstrated that TET is capable of protecting against more than 80 percent of noise treatment-induced damage.

As the firm’s cofounder and CEO Jianxin Bao, PhD, described it, the US Food and Drug Administration (FDA) has not approved any therapeutics against NIHL to-date, which is a major worldwide health issue that can result in tinnitus, or a persistent ringing in the ears. The plan is to rapidly transition TET into clinical studies that can help bring a therapy at the vanguard of science to market.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s